Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceplene and IL-2 Maintenance in MDS
NCT01324960Phase 2Withdrawn
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Mar 2011
- Primary completion
- Dec 2014
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of histamine dihydrochloride, aldesleukin in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Planned start Mar 2011; status: withdrawn.
02
Drugs
histamine dihydrochloridealdesleukin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01324960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01324960.